Introduction
b-Lactam or azetidin-2-one is an important structural motif of the penicillin, cephalosporin, carbapenem, and carbecephem classes of antibiotics.
1 Naturally occurring as well as synthetic monobactams, such as nocardicins and tabtoxin, are also known for their unique antibacterial activities. 2e4 Besides their importance as the key structural component of b-lactam antibiotics, b-lactams have been attracting considerable interest in organic synthesis as versatile synthetic intermediates and chiral synthons. 5e13 In addition, the b-lactam scaffold has found new pharmaceutical applications other than its use as antibiotics, such as LHRH antagonists, 14 cholesterol absorption inhibitors, 15 and anticancer agents. 16e19 The ring strain of the b-lactam skeleton facilitates ring-opening reactions, 8, 20, 21, 22 and this unique property has been exploited for the synthesis of a variety of medicinally active compounds.
For the last couple of decades, a large number of b-lactam-based synthetic methods, collectively termed as 'b-lactam synthon method', has been developed. This method has provided highly efficient routes to a variety of non-protein amino acids, oligopeptides, peptidomimetics, and nitrogen-heterocycles, as well as biologically active natural and unnatural products of medicinal interest, such as indolizidine alkaloids, paclitaxel, docetaxel, taxoids, cyptophycins, lankacidins, etc. 5,7e13 In this report, we present an overview of the evolution of the methods for the synthesis of enantiopure b-lactams, and the applications of the 'b-lactam synthon method' for the synthesis of biologically active compounds of medicinal interest. Examples of the use of the rigid b-lactam scaffold for drug design and discovery are also described.
Asymmetric synthesis of b-lactams
The Staudinger keteneeimine [2þ2] cycloaddition and the chiral ester enolateeimine cyclocondensation are the two methods, which are most commonly used for the synthesis of b-lactams with excellent enantiopurity. Thus, these two synthetic methods are discussed in this section.
Staudinger keteneeimine [2D2] cycloaddition
In 1907, long before the antibacterial activity of penicillin was discovered, Staudinger reported the first synthesis of a b-lactam, 1,3,3,4-tetraphenylazetidin-2-one, through the [2þ2] cycloaddition of diphenylketene with a Schiff base derived from aniline and benzaldehyde. 23 Subsequently, the scope of this reaction has been extended to alkyl-, amino-, halo-, alkoxy-, and siloxy-ketenes, as well as imino esters. Because of its broad scope in substrate structures and simplicity in experimental procedure, this reaction is regarded as one of the most reliable routes to b-lactams.
1 However, in spite of common practice in laboratory synthesis for decades, the mechanistic details of this reaction have been disputed and subjected to theoretical investigations since its inception. 24, 25 The most widely accepted mechanism is a two-step reaction process, which involves the nucleophilic attack of the imine nitrogen on the electrophilic central carbon of a ketene, generated in situ from an acid chloride and a base, to form a zwitterionic intermediate, followed by conrotatory ring closure to give the fourmembered ring system (Fig. 1) . 24, 25 In the reaction of a monosubstituted ketene with an aldimine, two chiral centers are introduced to the cycloadduct. Thus, the reaction would give either a single stereoisomer (i.e., cis or trans) of b-lactam or a mixture of cis-and trans-b-lactams, depending on the reactants and reaction conditions. 25, 24 As Fig Theoretical studies on the origin of the stereoselectivity suggest that the relative transition-state energy in the rate-determining step is dictated by electronic torque selectivity. 30, 31 The stereoselectivity of the reaction is influenced by reaction variables such as temperature, solvent, base, additives, chiral pendant groups, order of addition of reagents, microwave irradiation, etc.
32e34 For example, it has been shown that non-polar solvents favor the formation of cis-b-lactam whereas polar solvents facilitate trans-b-lactam formation. The result was explained by the stabilization of the zwitterionic intermediate in a polar solvent, promoting isomerization to the energetically more stable intermediate bearing the (Z)-imine moiety before conrotatory ring closure. 32 Asymmetric keteneeimine [2þ2] cycloaddition can be performed using combinations of (i) a chiral imine with an achiral ketene, (ii) a chiral ketene with an achiral amine or (iii) a chiral ketene with a chiral imine.
Asymmetric [2þ2] cycloaddition of achiral ketenes and chiral
imines. Chiral imines can be prepared either from chiral amines or from aldehydes. However, the diastereoselectivity of the reaction is lower, in most cases, using a chiral imine from a chiral amine, as compared to that from a chiral aldehyde. 35 Nevertheless, chiral amine sources are widely used for the asymmetric synthesis of b-lactams. 9, 36 For example, the reaction of phthalimidoacetyl chloride with chiral imine 1, derived from (R)-1-phenylethylamine, in the presence of triethylamine gave b-lactams 2 and 3 in 74% combined yield with high stereoselectivity (2/3¼9:1) (Scheme 1). 36 Commercially available enantiopure esters of a-amino acids are common sources of chiral amines. For example, 3-azido-b-lactam 5a (R¼triphenylsilyl¼TPS) was obtained in 64% yield and 19:1 dr (5a/6a) using imine 4a derived from (R)-O-TPS-threonine benzyl ester and cinnamaldehyde (Scheme 2). 37 The stereoselectivity of this reaction was found to depend critically on the bulkiness of the hydroxyl protecting group. Thus, the reaction of 4b (R¼tert-butyldimethylsilyl¼TBS) gave 5b with 9:1 dr (5b/6b) and that of 4c (R¼H) afforded a 1:1 mixture of 5c and 6c. 37 Alternatively, one of the most effective routes for a large-scale synthesis of b-lactams with high enantiopurity is to use chiral imines derived from chiral aldehydes such as a-oxyaldehydes and sugar-derived aldehydes (Scheme 3). 35,38e40 For example, the
[2þ2] cycloaddition of various ketenes with chiral imines 9 of Dglyceraldehyde acetonide (8) , derived from D-mannitol via 7, afforded cis-b-lactams 10 exclusively in 45e70% yield. 41, 42 The acetonide moiety of b-lactams 10 was deprotected to the corresponding b-lactam diols, which were oxidized by ruthenium tetroxide, followed by diazomethane esterification, to afford the 4-carbomethoxy-b-lactams. 41 The b-lactam diols were also converted into the corresponding 4-formyl-b-lactam 11, which are versatile synthetic intermediates for further manipulations.
13,42e44
When a chiral aldimine derived from a chiral aldehyde as well as a chiral amine was used, clear double asymmetric induction was observed, i.e., a matching pair gave the corresponding b-lactam as a single stereoisomer, while a mismatching pair afforded the blactam with only modest stereoselectivity. As Scheme 4 illustrates, the reaction of chiral aldimine 13, derived from (R)-threonine and chiral aldehyde 8 via 12, with a ketene, generated in situ from diphenyloxazolylacetyl chloride and triethylamine, gave a 1:2.9 mixture of b-lactams 14 and 15 (i.e., mismatching pair reaction), while the reaction using chiral aldimine 16, derived from (S)-threonine and 8, afforded b-lactam 17 exclusively in 69% yield for two steps (i.e., matching pair reaction). It has been shown that the [2þ2] cycloaddition of polyaromatic imines and ketenes, generated from acetoxy, phenoxy, and phthalimidoacetyl chloride and an amine base, exclusively gives trans-blactams, which makes a sharp contrast to the normal reaction pattern, yielding cis-b-lactams from the same ketene sources and diarylaldimines. 16, 17 In a similar manner, the reaction of a chiral ketene, generated from alkoxyacetic acid 24 bearing an a-glycoside group, with chresenylaldimine 25 gave a 45:55 mixture of 26 and 27 in 70% combined yield (Scheme 6). These two b-lactams were readily separated by column chromatography and the hydrolysis of the sugar chiral auxiliary afforded the corresponding enantiopure trans-3-hydroxy-4-phenyl-b-lactams. This protocol has also been successfully employed for the kinetic optical resolution of cis-3-acetoxy-4-isobutenyl-b-lactam. 43, 50, 55 Although kinetic optical resolution does not have good 'atom economy', it should be noted that the method is still quite economical and easily scalable. In addition, both enantiomers serve as useful chiral building blocks in organic synthesis, especially for the synthesis of non-protein amino acids, peptides, and peptidomimetics. substituent to the imine carbon. The electrophilic ketene component is transformed into a nucleophilic zwitterionic enolate through the addition of a nucleophilic catalyst to the central carbon of the ketene component. Then, the nucleophilic attack of the zwitterion on the a-carbon of the imine leads to the CeC bond formation, followed by cyclization to give b-lactam 37 and regenerates the catalyst 32. This reaction mechanism logically led to the realization of the fact that a catalyst for this reaction does not have to be a metal ion or charged and thus nucleophilic organocatalysts should be effective as well. 58 It was also hypothesized and proven that an organocatalyst, containing a nucleophilic center (e.g., tertiary amine) as well as an electrophilic center (e.g., hydrogen-bonding acceptor), would rigidify the key intermediate and the transition state to yield b-lactams with higher diastereoselectivity than that without the electrophilic center. 58 In order to accomplish the catalytic asymmetric synthesis of blactams based on this process, a number of optically active cinchona alkaloids were screened as potential chiral organocatalysts, and benzoylquinine (38) was found to give best results. Thus, the reaction of acid chlorides 39 with imine 36 in the presence of 38 as catalyst (10 mol %) and a proton sponge gave b-lactams 40 with 95e99% ee and 96:4 to 99:1 dr in 36e65% yield (Scheme 9). 58 In order to improve the chemical yield, metal salts were explored as effective co-catalysts to further activate imines. 59 Then, it was found that the use of triflates of Sc(III), Al(III), Zn(II), and In(III) (10 mol %) with 38 (10 mol %) gave b-lactams 40 in excellent yield and enantioselectivity (96e98% ee) as well as high diastereoselectivity (9:1 to 60:1 dr) (Scheme 10). Among the metal salts examined, In(OTf) 3 gave the best results followed by Zn(OTf) 2 , while Al(OTf) 3 and Sc(OTf) 3 were less effective. to-good yields and excellent enantioselectivity 61 (Scheme 12).
Another NHC 45b was used as a catalyst for the reaction of arylketenes 49 with azodicarboxylate 50, which afforded aza-blactams 51 in fairly good-to-excellent yields and 33e91% ee (Scheme 12).
62
C-2 symmetric imidazolinium catalyst 52 and chiral triazolium catalyst 53 have been used in the reaction of diphenylketene (34) with N-tosylaldimines 54 to give the corresponding b-lactams 55 in high yields and 55e75% ee (Scheme 13). 63 It has also been shown that chiral imidazoli- . 71 It is of interest to note that Co 2 (CO) 8 was found to catalyze the regio-and stereospecific carbonylation of chiral aziridines as well, but with complete inversion of configuration at the more substituted carbon with alkyl or phenyl substituents. 72 This process exhibited its exceptional stereochemical integrity in the formation of extremely strained trans-bicyclic b-lactams, 8-aza-7-oxo-[4.2.0]bicyclooctanes, from cis-cyclohexeneaziridines. 72 However, this process has not been applied to asymmetric synthesis.
Asymmetric synthesis of b-lactams through ester enolateeimine cyclocondensation
The chiral lithium enolates generated in situ from N,N-bis(silyl) glycinates 76 reacted with N-PMP-arylaldimines 77 to give trans-3- amino-b-lactams 78 exclusively in fairly good yields and excellent enantiopurity. 73 Among the various chiral ester auxiliaries screened, (À)-menthyl and (À)-2-phenylcyclohexyl were found to be highly effective for this reaction. For example, the reaction of 76a (R*¼(À)-menthyl) and 76b (R*¼(À)-2-phenylcyclohexyl) with N-PMP-benzaldimine (77a) in the presence of LDA in THF at À78 C afforded (3R,4R)-b-lactam 78a with >99% ee in 65 and 58% yields, respectively (Scheme 18). 73 Under the same conditions, the re- It has also been shown that the chiral ester enolateeimine cyclocondensation is a highly efficient method for the asymmetric synthesis of 3-hydroxy-b-lactams with excellent enantiopurity. 7, 8 In contrast to the rigid bissilylamino moiety in glycinates 76, the O-protected hydroxyl group is very flexible in hydroxyacetates 79. Thus, both the chiral auxiliaries and the O-protecting groups were screened to find the optimal chiral ester enolate 80 for this process. Then, the combination of TIPS and (À)-or (þ)-2-phenylcyclohexyl groups was found to achieve the best results. It should be noted that, in contrast to the reactions of 76, cis-blactams 82 were formed exclusively in this process. Chiral enolate 80 was generated from (À)-2-phenylcyclohexyl TIPSO-acetate 79 with LDA in THF at À78 C for 2 h. N-TMS-arylaldimines 81 (R 2 ¼TMS) were added to the enolate solution and reacted at À78 C and then gradually warmed to room temperature to give (3R,4S)-3-TIPSO-4-aryl-b-lactams 82 with 96e98% ee in 80e85% yield (Scheme 19). 74, 75 It is worthy of note that (3R,4S)-3-TIPSO-4-phenyl-b-lactam 82a (Table 1) serves as a key intermediate for the highly efficient semisynthesis of paclitaxel and docetaxel (vide infra). 74, 76 Although N-TMS-imines 81 (R 2 ¼TMS) are efficient to produce b-lactams 82 (R 3 ¼H) with free NH directly, those imines are limited to arylaldimines due to the instability of N-TMS-alkylaldimines. Thus, N-PMP-imines 81 (R 2 ¼PMP) were employed to successfully expand the scope of this reaction. Table 1 summarizes representative results, including those for N-TMS-imines 81 (R 2 ¼TMS).
74,75,77
An asymmetric estereenolate cyclocondensation process mediated by a ternary chiral ether ligandelithium amide complex was developed. The reaction of lithium enolate 83, generated from the corresponding 3-pentyl alkanoate (2 equiv) and LDA (2.2 equiv), with N-PMP-aldimine 84 in the presence of (1S,2S)-1,2-dimethoxy-1,2-diphenylethane (86) (2.6 equiv) and additional lithium amide, e.g., LiN(Pr-i)Cy and LiNCy 2 , (2.2 equiv) gave blactam 85 in 12e85% yield and 26e90% ee (Scheme 20). 78 The yield and enantioselectivity depend on the structure of the lithium amide used. For example, the reaction of 83a (R 1 ¼Me) with 84a (R 2 ¼Ph) using LiN(Pr-i)Cy afforded 85a in 85% yield and 88% ee, while the same reaction using LiN(Bu-t)Cy gave 85a in 22% yield and 55% ee.
Synthesis of amino acids, dipeptides and their derivatives
by means of b-lactam synthon method
Asymmetric synthesis of non-protein amino acids
Non-protein amino acids are amino acids, which are not produced from protein amino acids by post-translational modification and these amino acids do not have a specific transfer-RNA and codon triplet, and thus the main chains of proteins do not have these amino acid residues. 79 Since various non-protein amino acids are important components of medicinally important compounds, enantiopure a-alkyl-a-amino acids is not easy because conventional enzymatic resolution cannot be applied effectively. Fortunately, the b-lactam synthon method provides highly efficient routes to a-alkyl-a-amino acids with high enantiopurity through extremely stereoselective alkylation of 3-amino-b-lactams.
Two protocols have been developed for asymmetric alkylations,
i.e., (i) the alkylation of the C-3 position of a b-lactam (Type 1) and
(ii) the alkylation of the side chain ester enolate (Type 2) (Fig. 2) . 7, 9 As Fig. 2 In this process, the double alkylation took place exclusively at C1 0 and the absolute configuration of C1 0 was controlled by changing the order of addition of the two alkyl halides (Scheme 25).
9,85
The highly efficient triple alkylation of 105 was also achieved through sequential Type 2 double alkylation and Type 1 alkylations (Scheme 26) 9, 85 For example, sequential double alkylation of blactam 105 with methyl iodide and allyl bromide proceeded in the same manner as that in Scheme 25, giving 107b (>99% de), which was followed by the third (Type 1) alkylation with methyl iodide to afford 109 (>99% de) uneventfully in 80% yield for three steps. 114 with various amino acid esters 115 proceeded smoothly to give the corresponding dipeptides 116, bearing an isoserine residue at the N terminus, in high yields without epimerization or racemization under mild conditions without any coupling agent (Scheme 28). Proline methyl ester as well as the Wang resin-bound amino acids were also successfully employed for this coupling. 7, 94 The high efficiency and atom economy in this ring-opening coupling process is one of the most salient features of the b-lactam synthon method. It is also worthy of note that enantiopure N-Boc-3-siloxy-b-lactams were readily converted into the corresponding hydroxyethylene isosteres and dihydroxyethylene isosteres, which are key components in various enzyme inhibitors, mimicking tetrahedral intermediates. 95, 96 It has been shown that the incorporation of fluorine(s) into a medicinally active compound often improves its pharmacological properties, such as increased membrane permeability, enhanced hydrophobic binding, and stability against metabolic oxidation among other merits. 43, 97, 98 As fluorine is absent in living tissue, the incorporation of fluorine(s) into biologically relevant molecules as marker(s) provides a valuable means to monitor protein structures and dynamics as well as drugeprotein interactions in vitro and in vivo by 19 in modest-to-quantitative yields (Scheme 31). 13 Furthermore, the ring-opening coupling of b-lactams 121 with various a-and b-amino acid esters gave the corresponding dipeptides, 123 and 124, bearing fluoroisoserine residues, in 50e100% yields (Scheme 31) 13 [Note:
Scheme 31 only shows the reactions of (3R,4R)-121 for simplicity, but (3S,4S)-121 reacted in a similar manner.]. The Type 1 alkylation of 3-siloxy-b-lactams 125 proceeded with excellent diastereoselectivity to give 3-alkyl-3-siloxy-b-lactams 126 with >99% de, which were converted into NH-b-lactams via CAN deprotection, followed by acidic hydrolysis to afford the corresponding a-alkyl-a-hydroxy-b-amino acids 127 in excellent yields (Scheme 32). Fig. 3 ), a complex diterpene isolated from the bark of Taxus brevifolia (Pacific yew), is a leading FDA-approved drug for the treatment of advanced ovarian cancer (1992), breast cancer (1994), AIDS-related Karposi's sarcoma (1997), non-smallcell lung cancer (1999), and other cancers (Fig. 3) . 91 ,101,102 Docetaxel (Fig. 3) , the first semisynthetic analogue ('taxoid') of paclitaxel, was also approved by the FDA in 1996 against breast cancer and has been extensively used for the treatment of various cancers such as those of lung, ovarian, prostate, and others. 91, 92, 102 Paclitaxel and docetaxel are cytotoxic drugs, which act as mitotic spindle poisons by accelerating tubulin polymerization in The b-lactam synthon method has played a crucial role in the highly efficient semisynthesis of paclitaxel and docetaxel. For instance, paclitaxel was synthesized through ring-opening coupling of (3R,4S)-1-benzoyl-3-EEO-4-phenyl-b-lactam 132a (R¼Ph) with 7-TES-baccatin 133a (R 1 ¼Ac, P¼Et 3 Si) at the C13 position, affording 134a, followed by deprotection of the 1-ethoxyethyl (EE) and TES groups with 0.5% HCl in ethanol in high overall yield (Scheme 34). 7 
b-
Lactam 132a and this ring-opening coupling protocol were also employed to complete the total synthesis of paclitaxel.
107e110 In This highly efficient ring-opening coupling process, 'OjimaeHolton coupling', opened an avenue for the synthesis and structureeactivity relationship (SAR) studies on a variety of paclitaxel congeners, 'taxoids'. 76,77,115e119 The standard procedure for the coupling quickly evolved to the use of 1-acyl-or 1-carbalkoxy-3-TIPSO-b-lactams and LiHMDS as the base. 7 Extensive SAR studies on taxoids have led to the discovery of highly potent new-generation taxoids, which have modifications at C3 0 , C10 and/or C2 and possess 2e3 orders of magnitude higher potencies than paclitaxel and docetaxel against multidrug resistant (MDR) as well as paclitaxel-resistant cancer cell lines. Selected newgeneration taxoids exhibit much better efficacy than paclitaxel and docetaxel against human tumor xenografts in animal models. 77,117e119 Selected new-generation taxoids are listed in Table 2 and their in vitro activities against several cancer cell lines in Table 3 . In order to investigate the bioactive conformation of paclitaxel, conformationally restricted macrocyclic paclitaxel congeners were designed and synthesized by using a combination of the b-lactam synthon method and an intramolecular Heck reaction or Rucatalyzed ring-closing metathesis (RCM). For example, a 3 0 NeC2-linked novel macrocyclic taxoid 138 was synthesized using an intramolecular Heck reaction in the macrocyclization step (Scheme 35). Table 1 ). The ring-opening coupling of 135 with 2-(2-vinylbenzoyl)-7-TES-baccatin (136) under the standard conditions gave the iodo-vinyl-taxoid 137 in high yield. The intramolecular Heck reaction of 137 catalyzed by a Pd(0)eAsPh 3 complex at 55 C, followed by deprotection afforded the 19-membered exo-methylene-macrocyclic taxoid 138 in 56% yield. The macrocyclic taxoid 138 exhibited a very good IC 50 value of 67 nM against LCC6-WT human breast cancer cell line. The RCM of 141a using the first-generation Grubbs Ru catalyst at room temperature, followed by deprotection of the silyl groups, gave the expected 15-membered macrocyclic taxoid SB-T-2053 in high yield (Scheme 36). 120, 122 give the 15-membered macrocyclic taxoid SB-T-2054, in which the double bond of the linkage was conjugated to the benzoyl moiety, in good yield after deprotection (Scheme 36). 120 This novel coupling reaction is mediated by the Ru complex, but not catalytic, and likely to involve Rueallyl complexes as key intermediates. 120 These macrocyclic taxoids were examined for their activities in tubulin polymerization and microtubule stabilization as well as their potencies against six human cancer cell lines. It was found that both SBT-2053 and SBT-2054 possessed virtually the same activity as that of paclitaxel in the tubulin polymerization/depolymerization assay. Moreover, SBT-2054 was found to be as potent as paclitaxel in the cytotoxicity assay, which is the closest conformationally restricted paclitaxel congener to date, mimicking the binding structure of paclitaxel in microtubules.
120,123
Synthesis of cryptophycins by means of N-acyl-b-lactam macrolactonization
Cryptophycins are macrocyclic cytotoxins produced by cyanobacteria, which exhibit potent tumor-selective antitumor activities by binding microtubules and disrupting cellular mitosis (Fig. 4) . These compounds are particularly active against MDR cancer cell lines. Synthetic cryptophycin-52 (Cr-52) is currently under clinical development for treatment against solid tumors and has shown an exceptionally potent cytotoxicity against the MCF-7 breast cancer cell line (IC 50 ¼0.037 nM). 124 Dechlorocryptophycin-52 also exhibits good activity in the tubulin assembly assay (IC 50 ¼3 mM; for Cr-1, IC 50 ¼2.5 mM) and excellent cytotoxicity against the MCF-7 cell line (IC 50 ¼0.3 nM). 124 An efficient synthesis of the macrolide core of cryptophycins has been achieved by using the N-acyl-b-lactam macrolactonization protocol. 125, 126 The key steps in the total synthesis of cryptophycin-24 (arenastatin A) are illustrated in Scheme 37, which represents the synthetic strategy for this class of compounds. 126 The key b- ring opening using Bu 4 NCN and subsequent lactonization to give the 16-membered macrocycle 145 in 68% yield. The attempted direct ring-opening coupling using NaH and NaHMDS as base was unsuccessful, presumably due to the instability of 144 under basic conditions. The introduction of the C3 0 -phenyl moiety through the Heck reaction gave the desired product, but only in modest yield. Epoxidation of the resulting styryl double bond with dimethyldioxirane (DMD) gave cryptophycin-24 as a 2:1 (b/a) diastereomeric mixture, which was separated by reverse-phase HPLC. This strategy was also employed for the total synthesis of dechlorocryptophycin-52. The b-lactam synthon method was applied to the construction of the indolizidine skeleton through ring-expansion of piperidinyl-blactams 153 (Scheme 40). 132 The preparation of b-lactams 153 is illustrated in Scheme 39. An aza-DielseAlder reaction of b-lactam 150 with Danishefsky's diene 151 gave a 3:1 mixture of cycloadducts 152a and 152b, which were separated by column chromatography. 132 
b-
Lactam 152a was reduced successively with L-Selectride and NaBH 4 to give a 3:2 mixture of epimeric alcohols, which were protected with TBS and separated by chromatography to afford piperidinyl-b-lactams 153a and 153b. It is interesting to note that the same reductioneprotection sequence for b-lactam 152b gave 153c exclusively. 133 The ring-expansion reaction of three piperidinyl-b-lactams, 153a, 153b, and 153c, catalyzed by sodium methoxide proceeded smoothly at 0 C to afford the corresponding epimeric indolizidines, 154a, 154b, and 154c, respectively, in quantitative yields (Scheme 40). 133 Although the preparation of piperidinyl-b-lactams needs improvements, the ring-expansion process is highly efficient and this methodology can be applied to the construction of other izidine alkaloid skeletons. Scheme 38.
Formation of pyrrolidines through one-carbon ring-expansion of b-lactams
The reaction of (2R,3R)-3-alkoxy-4-formyl-b-lactams 11 (see Scheme 3) with t-BuMe 2 SiCN (TBSCN) catalyzed by molecular iodine gave 5-cyanopyrrolidin-2-ones 163 in moderate-to-high yield with high syn selectivity (86e100%) (Scheme 43). 139, 140 The syn/anti selectivity depends mostly on the N-substituents and PMP gave the best results, i.e., 100% syn selectivity. This skeletal rearrangement involves the C3eC4 bond cleavage, acyliminium ion formation, and cyanide addition. This mechanism was supported by a DFT calculation using 4-formyl-b-lactam 11 (R 1 ¼Me, R 2 ¼Ph) and TMSCN.
Other nucleophiles such as allyltrimethylsilanes and propargylsilane can be used in this unique reaction.
139
The ring-expansion reaction of enantiopure 4-(arylimino)-blactams 164, which were readily derived from 4-formyl-b-lactams 11 with arylamines, in the presence of a catalytic amount of tetrabutylammonium cyanide (Bu 4 NCN) proceeded smoothly in acetonitrile at room temperature to give the corresponding 5-aryliminopyrrolidin-2-ones 165 without racemization in 44e70% yields via N1eC4 bond breakage (Scheme 43). 141 The acidic hy- 166 in 50e55% yields, which were better than the overall yields in the original three-step process (Scheme 41). 141 
Formation of six-membered nitrogen-heterocycles via two-carbon ring-expansion of b-lactams
Reduction of 4-(2-TBSO-ethyl)-b-lactams 167 with monochloroalane, followed by TBS deprotection and mesylation, gave 2-(2-TBSO-ethyl)azetidines 168 in three steps. The subsequent reaction of 168 with sodium acetate in acetonitrile, followed by basic hydrolysis, gave cis-3-alkoxy/phenoxy-4-hydroxypiperidines 170 in moderate overall yields through two-carbon ring-expansion (Scheme 44). 142 This ring-expansion process involves the ammo- ¼i-Pr) with LiBr in acetonitrile gave cis-3-alkoxy-4-bromopiperidine 171, which was converted into piperidin-3-one 172 via the enol-ether in fairly good yield for two steps (Scheme 44). The reaction of 4-acyloxy-b-lactams 179 with an acid chloride and DBU afforded 1,3-oxazin-6-ones 180 in modest-to-good yields (Scheme 46). 146 The mechanism of this unique process is likely to involve the formation of highly strained N-acylazetone 181, which rapidly undergoes electrocyclic ring opening to generate N-acylimidoylketene 182. Then, the cyclization of 182 gave 1,3-oxazin-6-one
MeO OMe Cl 
180.
147 A theoretical study on this reaction based on ab initio and DFT analysis has confirmed that two pseudopericyclic reactions are involved. The first key reaction is a retro-[4-exo-dig] cyclization to generate 183 instead of a thermal conrotatory electrocyclic ring opening, followed by another exothermic pseudopericyclic reaction to form 180 in place of a six-electron disrotatory electrocyclization. 146 The C3eC4 bond cleavage of 4-formyl-b-lactam 183a (X¼O) and 4-arylimino-b-lactam 183b (X¼ArN) was mediated by stannous chloride and the subsequent six-membered ring formation gave 1,4-dihydrooxane 184a (X¼O) and pyrazine-2,3-dione 184b (X¼ArN), respectively, in good-to-excellent yield (Scheme 47). 
-Lactam cholesterol absorption inhibitors
Atherosclerotic coronary heart disease (CHD) is the major cause of death in the United States, and it has been shown that CHD is associated with elevated serum cholesterol levels, to which cholesterol from dietary or intestinal sources is the major contributor. 15 Accordingly, the serum cholesterol level should be effectively controlled by blocking the intestinal sources of cholesterol. Then, the cholesterol absorption in the intestine can be blocked by inhibiting acyl-CoA:cholesterol O-acyltransferase (ACAT). 15 Thus, ACAT inhibitors have been extensively studied, including b-lactams, which led to the discovery of ezetimibe, a trans-b-lactam, as a potent and highly efficacious cholesterol absorption inhibitor. and removal of the benzyl protection by hydrogenolysis, afforded ezetimibe with >99% ee in good overall yield. 150 
b-Lactam-based combretastatin mimics
Combretastatins are naturally occurring diarylstilbenes, isolated from the stem of Combretum caffrum (South African bushwillow tree). 151, 152 These compounds exhibit strong cytotoxicity and are known to share the same tubulin-binding site as colchicine. 153 Among these, the highly potent combretastatin A-4 was selected for drug development and its phosphate derivative, combretastatin A-4-phosphate, a water-soluble prodrug, is currently in clinical trials for the treatment of thyroid cancer (Fig. 6) . 152, 154 As the cisolefin moiety of combretastatin A-4 is prone to isomerization, which causes a loss of activity, the rigid b-lactam ring system was used to develop a series of b-lactam-based structurally stable combretastatin mimics, some of which exhibited promising activities (Fig. 6 ).
19
Combretastatin A-4 mimic 197a was synthesized via the Reformatsky reaction of phenylbromoacetate 198 and imine 199, followed by desilylation (Scheme 52). 19 Mimics 197b and 197c were synthesized through the Staudinger keteneeimine cycloaddition reaction of ketenes generated from 200a and 200b with imine 199, forming b-lactams 201a and 201b, respectively, followed by desilylation and reductive removal of the benzyl or Cbz group (Scheme 52). 19 The reported chemical yields for these mimics are modest, at best, for some reason. The IC 50 values of these mimics were determined to be 9.6, 0.8, and 4.5 nM, respectively, indicating that they are as potent as, or more potent than, combretastatin A-4 against the MCF-7 human breast cancer cell line. 19 Although these mimics have been found to be potent and promising, a substantial improvement in the syntheses is necessary for their further development as drug candidates.
b-Lactam-based novel vasopressin V1a antagonists
Vasopressin and oxytocin are neurohypophysical hormones, which bind to specific receptors of the G protein-coupled receptor (GPCR) superfamily. 155 Vasopressin V1a, V1b and oxytocin receptors activate phospholipase C, which leads to secretion of inositol 1,4,5-triphosphate and diacylglycerol that mobilize intracellular calcium and activation of protein kinase C. 155 Besides their functions in the cardiovascular system, vasopressin antagonists have been recommended for some CNS applications. 156 receptor, LY307174 (IC 50 ¼45 nM for human V1a receptor) was identified as the lead structure for extensive SAR studies (Fig. 7 ).
14 After systematic SAR studies, two highly potent compounds, 202a (SRX246) and 202b (SRX251) (Fig. 7 and Scheme 53) were discovered, which exhibited K i values of 0.3 and 0.66 nM, respectively. When administered orally, these two compounds reached ca. 100-fold higher brain levels in rats than their in vitro receptor affinities. Thus, these two compounds are currently under drug development for human clinical evaluation. 14 The synthetic routes to 202a and 202b are illustrated in Scheme 53. derivatives and peptides as well as biologically active natural and unnatural compounds of medicinal interest. In addition, the discovery and development of novel b-lactams with anticancer activity, cholesterol absorption inhibitory activity and CNS activity by exploiting the rigid and unique b-lactam scaffold are described. Traditionally, the organic chemistry and medicinal chemistry of blactams have been directly related to b-lactam antibiotics. However, it is obvious that the potential of b-lactams has been explored extensively in an impressive breadth, which has created an entirely new field of chemical and medicinal research. Thus, it is safe to say that this field of research will continue to expand and flourish.
